Ceradyne's Q2 2012 earnings transcript reveals multiple challenges likely to curtail short-term stock performance. The sharp revenue decline from losing high-margin products, a reduction in the EPS guidance, delays in key contracts, and issues with the Solar Crucible business, along with European economic concerns, indicate immediate negative impacts. The stock might face headwinds in the near term, which could pressure its price.

[-1]